HiFiBiO Therapeutics

Expectations were not high for the latest trial of FibroGen, Inc. ’s pamrevlumab in Duchenne muscular dystrophy (DMD); nevertheless, the connective tissue growth factor-targeted product has still con

Venture capital investors have not taken the summer off, at least not during the first few weeks of June, continuing to support mega-rounds of $100m or more for biopharmaceutical companies with novel

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Roche Exits Gene Therapy Delivery Pact

Kite Pharma, Inc. CEO Christi Shaw is optimistic about Gilead Sciences, Inc. maintaining a leadership position in cancer cell therapy, especially as its second CAR-T therapy Tecartus appears poised